Literature DB >> 32614391

Estrone Is a Strong Predictor of Circulating Estradiol in Women Age 70 Years and Older.

Susan R Davis1, Alejandra Martinez-Garcia1,2, Penelope J Robinson1, David J Handelsman3, Reena Desai3, Rory Wolfe4, Robin J Bell1.   

Abstract

IMPORTANCE: After menopause, estradiol (E2) is predominately an intracrine hormone circulating in very low serum concentrations.
OBJECTIVE: The objective of this work is to examine determinants of E2 concentrations in women beyond age 70 years. DESIGN AND
SETTING: A cross-sectional, community-based study was conducted. PARTICIPANTS: A total of 5325 women participated, with a mean age of 75.1 years (± 4.2 years) and not using any sex steroid, antiandrogen/estrogen, glucocorticoid, or antiglycemic therapy. MAIN OUTCOME MEASURES: Sex steroids were measured by liquid chromatography-tandem mass spectrometry. Values below the limit of detection (LOD; E2 11 pmol/L [3 pg/mL] were assigned a value of LOD/√2 to estimate total E2.
RESULTS: E2 and estrone (E1) were below the LOD in 66.1% and 0.9% of women, respectively. The median (interdecile ranges) for E1 and detectable E2 were 181.2 pmol/L (range, 88.7-347.6 pmol/L) and 22.0 pmol/L (range, 11.0-58.7 pmol/L). Women with undetectable E2 vs detectable E2 were older (median age 74.1 years vs 73.8, P = .02), leaner (median body mass index [BMI] 26.8 kg/m2 vs 28.5, P < .001), and had lower E1, testosterone and DHEA concentrations (P < .001). A linear regression model, including age, BMI, E1, and testosterone, explained 20.9% of the variation in total E2, but explained only an additional 1.2% of variation over E1 alone. E1 and testosterone made significant contributions (r2 = 0.162, P < .001) in a model for the subset of women with detectable E2.
CONCLUSIONS: Our findings support E1 as a principal circulating estrogen and demonstrate a robust association between E1 and E2 concentrations in postmenopausal women. Taken together with prior evidence for associations between E1 and health outcomes, E1 should be included in studies examining associations between estrogen levels and health outcomes in postmenopausal women. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  estradiol; estrone; postmenopause

Mesh:

Substances:

Year:  2020        PMID: 32614391      PMCID: PMC7394338          DOI: 10.1210/clinem/dgaa429

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  31 in total

1.  Exploration of dimensions of estrogen potency: parsing ligand binding and coactivator binding affinities.

Authors:  M Jeyakumar; Kathryn E Carlson; Jillian R Gunther; John A Katzenellenbogen
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

2.  Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy.

Authors:  Marie L Misso; Christina Jang; Jennifer Adams; Jane Tran; Yoko Murata; Robin Bell; Wah Chin Boon; Evan R Simpson; Susan R Davis
Journal:  Menopause       Date:  2005-03       Impact factor: 2.953

Review 3.  A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review.

Authors:  James A Simon; David F Archer; Ginger D Constantine; James H Pickar; Julia M Amadio; Brian Bernick; Shelli Graham; Sebastian Mirkin
Journal:  Maturitas       Date:  2017-02-16       Impact factor: 4.342

Review 4.  All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause.

Authors:  Fernand Labrie
Journal:  J Steroid Biochem Mol Biol       Date:  2014-06-09       Impact factor: 4.292

5.  Testosterone and Estrone Increase From the Age of 70 Years: Findings From the Sex Hormones in Older Women Study.

Authors:  Susan R Davis; Robin J Bell; Penelope J Robinson; David J Handelsman; Tom Gilbert; James Phung; Reena Desai; Jessica E Lockery; Robyn L Woods; Rory S Wolfe; Christopher M Reid; Mark R Nelson; Anne M Murray; John J McNeil
Journal:  J Clin Endocrinol Metab       Date:  2019-12-01       Impact factor: 5.958

Review 6.  Aromatase expression and regulation in breast and endometrial cancer.

Authors:  Hong Zhao; Ling Zhou; Anna Junjie Shangguan; Serdar E Bulun
Journal:  J Mol Endocrinol       Date:  2016-04-11       Impact factor: 5.098

7.  Sensitive routine liquid chromatography-tandem mass spectrometry method for serum estradiol and estrone without derivatization.

Authors:  Steven Pauwels; Leen Antonio; Ivo Jans; Anneleen Lintermans; Patrick Neven; Frank Claessens; Brigitte Decallonne; Jaak Billen; Dirk Vanderschueren; Pieter Vermeersch
Journal:  Anal Bioanal Chem       Date:  2013-07-28       Impact factor: 4.142

8.  Estrogen sulfotransferase: intracrinology meets metabolic diseases.

Authors:  Franck Mauvais-Jarvis
Journal:  Diabetes       Date:  2012-06       Impact factor: 9.461

9.  Sex-specific Estrogen Levels and Reference Intervals from Infancy to Late Adulthood Determined by LC-MS/MS.

Authors:  Hanne Frederiksen; Trine Holm Johannsen; Stine Ehlern Andersen; Jakob Albrethsen; Selma Kløve Landersoe; Jørgen Holm Petersen; Anders Nyboe Andersen; Esben Thyssen Vestergaard; Mia Elbek Schorring; Allan Linneberg; Katharina M Main; Anna-Maria Andersson; Anders Juul
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

10.  Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study.

Authors:  Roni T Falk; Louise A Brinton; Joanne F Dorgan; Barbara J Fuhrman; Timothy D Veenstra; Xia Xu; Gretchen L Gierach
Journal:  Breast Cancer Res       Date:  2013-04-22       Impact factor: 6.466

View more
  2 in total

Review 1.  Sex differences in autonomic responses to stress: implications for cardiometabolic physiology.

Authors:  Carley Dearing; Robert J Handa; Brent Myers
Journal:  Am J Physiol Endocrinol Metab       Date:  2022-07-06       Impact factor: 5.900

2.  Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial.

Authors:  Rakibul M Islam; Robin J Bell; David J Handelsman; John J McNeil; Mark R Nelson; Christopher M Reid; Andrew M Tonkin; Rory S Wolfe; Robyn L Woods; Susan R Davis
Journal:  Lancet Healthy Longev       Date:  2022-02-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.